Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia 1Graft vs Host Disease 1

Interventions

Cytarabine 899Cyclophosphamide 894fludarabine 517venetoclax 475fludarabine phosphate 464Azacitidine 452Rituximab 418Methotrexate 415Etoposide 319Filgrastim 299Busulfan 295Dexamethasone 285Vincristine 281Daunorubicin 280Peripheral Blood Stem Cell Transplantation 257Whole-Body Irradiation 240Mycophenolic Acid 231Decitabine 228Granulocyte Colony-Stimulating Factor 225Tacrolimus 219Idarubicin 203Melphalan 201Imatinib Mesylate 195Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 161Mitoxantrone 160Lenalidomide 159Mercaptopurine 155

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × eritoran × Other hematologic neoplasm × Clear all
NCT00756912 2014-07-11

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Eisai Inc.

Phase 1 Terminated
30 enrolled
Other hematologic neoplasm

Graft vs Host Disease, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡